Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.51 |
| ▸ | FABP7 | O15540 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779340 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30781736 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL47693 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL5497604 | 0.86 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL846010 | 0.84 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL10071038 | 0.84 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL20820035 | 0.84 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30977665 | 0.84 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL3888794 | 0.83 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14612149 | 0.83 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12030834-B2 | Methods of synthesizing 4-valyloxybutyric acid | XWPharma Ltd. (KY) | 2024-07-09 | — | — | US | disclosed |
| US-20240067674-A1 | METHOD FOR LOADING AMINO ACID ON RESIN FOR SOLID-PHASE SYNTHESIS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | UNIVERSITY OF NOTRE DAME DU LAC | 2023-12-14 | — | — | US | disclosed |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230357130-A1 | METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID | XWPharma Ltd. (KY) | 2023-11-09 | — | — | US | disclosed |
| US-11779646-B2 | Dynamic user-programmable materials including stimuli-responsive proteins | UNIVERSITY OF WASHINGTON (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780842-B2 | TYK2 pseudokinase ligands | VENTYX BIOSCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| US-7388061-B2 | Solid catalyst component for polymerization of olefins, catalyst comprising the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-06-17 | — | — | US | disclosed |
| US-7338805-B2 | Labeling reagents, methods for synthesizing such reagents and methods for detecting biological molecules | BIO MERIEUX (FR) | 2008-03-04 | — | — | US | disclosed |
| US-20080009026-A1 | FLUOROGENIC PROTEIN KINASE SUBSTRATES | INVITROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-7312306-B2 | Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070196860-A1 | Methods for Measuring Real Time Kinase Activity | INVITROGEN CORPORATION (US) | 2007-08-23 | — | — | US | disclosed |
| US-7256253-B2 | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2007-08-14 | — | — | US | disclosed |
| US-20070154882-A1 | Beta-polypeptides that inhibit cytomegalovirus infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-05 | — | — | US | disclosed |
| EP-1518862-B1 | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution | GRYPHON THERAPEUTICS INC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20050239636-A1 | Solid catalyst component for polymerization of olefins, catalyst comprising the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | KMT2A 2012/4885FABP5 2241/4885FABP7 2593/4885 |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | HTR2A, HTR2C, HTR2B | KMT2A 1435/4885FABP5 910/4885FABP7 215/4885 |
| US-11779646-B2 | Dynamic user-programmable materials including stimuli-responsive proteins | MSN, SUMO2, PEBP1 | KMT2A 1779/4885FABP5 407/4885FABP7 613/4885 |
| US-11780842-B2 | TYK2 pseudokinase ligands | TYK2, JAK2, PTK2B | KMT2A 901/4885FABP5 4217/4885FABP7 4210/4885 |
| US-20080300287-A1 | Peptidic Compounds | VIP, NGLY1, FURIN | KMT2A 4643/4885FABP5 1385/4885FABP7 3170/4885 |
| US-20240067674-A1 | METHOD FOR LOADING AMINO ACID ON RESIN FOR SOLID-PHASE SYNTHESIS | SLC7A5, SLC7A1, MAX | KMT2A 2228/4885FABP5 1822/4885FABP7 2364/4885 |
| US-12030834-B2 | Methods of synthesizing 4-valyloxybutyric acid | GABBR1, GABBR2, GABRB3 | KMT2A 2039/4885FABP5 464/4885FABP7 479/4885 |
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | KMT2A 2517/4885FABP5 639/4885FABP7 867/4885 |
| US-20230357130-A1 | METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID | GABBR1, GABBR2, GABRB3 | KMT2A 2039/4885FABP5 464/4885FABP7 479/4885 |
| US-20070196860-A1 | Methods for Measuring Real Time Kinase Activity | MAP4K5, MAP3K9, MAP4K2 | KMT2A 1798/4885FABP5 1616/4885FABP7 1181/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | KMT2A 1890/4885FABP5 2184/4885FABP7 2416/4885 |
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | APP, MAPT, NEFM | KMT2A 2854/4885FABP5 3385/4885FABP7 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.